As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
How you can devise a cancer prevention action plan.
How to love yourself — and your selfies — without filters or fillers.
Treatment Study for Patients with Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Clinical Trial Title:
Pazopanib neoadjuvant trial in non-rhabdomyosarcoma soft tissue sarcomas (PAZNTIS): A phase II/III randomized trial of preoperative chemoradiation or preoperative radiation plus or minus pazopanib.
Clinical Trial Protocol ID:
15011502-CAOl
Clinical Trial Investigator Name:
Mary Lou Schmidt, MD
Clinical Trial Protocol Description:
To identify the dose of pazopanib that is feasible when given in combination with radiation or chemo-radiation in pediatric and adult patients with unresected intermediate- and high-risk NRSTS.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are older than 2 years of age at the time of the biopsy that established the diagnosis of NRSTS.
-
Have been newly diagnosed and histopathologically confirmed, potentially resectable NRSTS of the extremity and trunk. Patients will be eligible for the chemotherapy or non-chemotherapy cohort based on:
- Evidence of chemotherapy sensitivity of the histologic sarcoma subtype based on existing evidence from prior clinical trials.
- Sufficient risk of metastatic disease to warrant chemotherapy based on size and grade.
This is a partial list of elgibility requirements.
Clinical Trial Area:
Sarcomas
Contact Phone:
(312) 355-0741
Contact Name:
Nitin Sane